RO-7239361 (BMS-986166)
Moderate to Severe Plaque Psoriasis
Key Facts
About Rohto Pharmaceutical
Founded in 1899, Rohto Pharmaceutical has built a dominant global franchise in consumer healthcare, particularly in eye drops and skincare, generating stable revenues and deep consumer trust. The company's core strategy involves using this financial strength to fund a strategic pivot into biopharmaceutical R&D, with a focused pipeline in ophthalmology, dermatology, and metabolic diseases. Its achievements include a formidable OTC brand portfolio, international distribution, and the advancement of several drug candidates, positioning it for long-term growth beyond its traditional market.
View full company profileAbout Rohto Pharmaceutical
Founded in 1899, Rohto Pharmaceutical has built a dominant global franchise in consumer healthcare, particularly in eye drops and skincare, generating stable revenues and deep consumer trust. The company's core strategy involves using this financial strength to fund a strategic pivot into biopharmaceutical R&D, with a focused pipeline in ophthalmology, dermatology, and metabolic diseases. Its achievements include a formidable OTC brand portfolio, international distribution, and the advancement of several drug candidates, positioning it for long-term growth beyond its traditional market.
View full company profileTherapeutic Areas
Other Moderate to Severe Plaque Psoriasis Drugs
| Drug | Company | Phase |
|---|---|---|
| OLUX-E (clobetasol propionate) Foam | Medimetriks Pharmaceuticals | Approved |